海欣品牌怎么样 申请店铺
外推网助力海欣品牌出海！通过在本页面挂载海欣品牌的产品链接和联系邮箱，可以提高海欣产品曝光！跨境电商爆单神器，目前只要100元/年哦~
上海海欣集团股份有限公司是一家以生产经营长毛绒产品为主，并已向医药产业和金融领域拓展的A、B股上市公司。前身为（中外合资）上海海欣有限公司，成立于1986年，1993年改制为股份公司。1993年12月和1994年4月，公司发行的B股和A股先后在上海证劵交易所上市。现为上海证劵交易所180指数样本股。
现在，公司的总股本约6亿股，其中B股约2亿股，A股约1.8亿股。总资产约33亿元人民币，净资产约18亿元人民币。
本公司进口日本原料从事研究开发长毛绒面料、涤纶和晴纶的纺丝/纱加工，及毛绒玩具、化纤毛毯、服装等相关纺织品生产，发展到现在的加工制造化学原料药物、生物制品、保健品、中药原料药和各类制剂等，并从事符合国家产业政策的投资业务和资产经营管理。
2002年企业加快了在全球范围内的优化资源配置步伐，抢滩北美，成功地收购了具有七十年历史的GLENOIT公司的纺织分部，及得到了46个可永久使用的品牌商标，并因此从亚洲毛绒生产大企业一跃成为世界毛绒生产巨头之一，在占全球60%服装市场的北美和加拿大占有一席之地。为此，企业主业之一的毛绒服装面料年生产能力已达到4000万米。目前以毛绒服装面料为主的产业已成为引导消费市场的国内骨干企业，设计配置多元化，正成为市场营销全球一体化的大型跨国企业，并计划迅速建立具有更大经济规模的服装生产企业，形成从面料到服装销售的品牌产品生产基地。
在医药领域，公司已投入近两亿元人民币，组建了海欣生物技术和西安华昊精英药业两家生物医药研发公司；投资设立了西安海欣制药、苏中海欣制药和赣南海欣药业三家医药生产企业；参股江苏苏中制药有限公司和上海延安万象药业股份有限公司，并控股上海生物技术工业园医药销售有限公司。形成了集研发、生产和销售三位一体的医药产业。医药产业正在成为公司重要利润的增长点之一。
在金融投资方面，公司以自有资金对长江证劵公司投资2.3亿元人民币，占其增资后的注册资本20亿元人民币的10%。本公司与长江证劵、武钢股份共同发起的长信基金管理有限公司已于2003年5月成立，注册资本9000万元人民币，其中，本公司出资占34.33%。
企业将来的经营目标是：保持经营业绩的持续稳步增长，进一步扩大纺织主业规模和市场占有率，加速调整公司产业结构；提高具有可观盈利空间的服装面料的比重，迅速发展壮大长毛绒服装产业，使之成为新的重要的利润增长点；加大纺织业新产品开发力度，提高新产品在销售额中的比重，积极拓展国内外纺织品市场；整合已具雏形的医药产业并取得可观的收益；根据公司跨行业、跨国经营的实际和发展要求，加强企业管理和企业文化建设。探索跨行业、跨地区的国际化企业集团管理模式；在主营业务收入和净利润等方面保持稳步的增长。未来五年，力争企业建设及规模从净资产18亿人民币增加到30亿元人民币；年净利润总额从1.57亿提高到3.5亿元人民币，形成精品纺织、生物医药和金融投资三位一体的多元化产业发展格局。
Shanghai Haixin Group Co., Ltd. is a listed company of a and B shares, which mainly produces and operates long plush products and has expanded to the pharmaceutical industry and financial field. The former is (Sino foreign joint venture) Shanghai Haixin Co., Ltd., which was founded in 1986 and restructured into a joint stock company in 1993. In December 1993 and April 1994, B shares and a shares issued by the company were listed on the Shanghai Stock Exchange successively. Now it is the sample stock of Shanghai Stock Exchange 180 index. At present, the total share capital of the company is about 600 million shares, including about 200 million B shares and about 180 million a shares. The total assets are about 3.3 billion yuan, and the net assets are about 1.8 billion yuan. The company imports Japanese raw materials to engage in the research and development of the spinning / yarn processing of plush fabrics, polyester and acrylic fiber, and the production of plush toys, chemical fiber blankets, clothing and other related textiles, and develops to the present processing and manufacturing of chemical raw materials drugs, biological products, health products, traditional Chinese medicine raw materials and various preparations, and engaged in investment business and asset management in line with national industrial policies 。 In 2002, the company accelerated the pace of optimizing resource allocation in the global scope, seized North America, successfully acquired the textile division of glonoit company with a history of 70 years, and obtained 46 brand trademarks that can be permanently used. Therefore, the company has become one of the world's largest plush producers from the Asian plush production enterprises, occupying one in North America and Canada, accounting for 60% of the global clothing market Place of seats. Therefore, the annual production capacity of plush clothing fabric, one of the main businesses of the enterprise, has reached 40 million meters. At present, the industry dominated by plush clothing fabrics has become a domestic backbone enterprise guiding the consumer market. With diversified design and configuration, it is becoming a large-scale transnational enterprise with global marketing integration. It is planned to rapidly establish a clothing production enterprise with a larger economic scale and form a production base of brand products from fabrics to clothing sales. In the field of medicine, the company has invested nearly 200 million yuan to establish two biomedical R & D companies: Haixin biotechnology and Xi'an Huahao elite pharmaceutical industry; three pharmaceutical production companies, Xi'an Haixin pharmaceutical, Suzhong Haixin pharmaceutical and Gannan Haixin pharmaceutical, have been invested and established; jiangsusu Pharmaceutical Co., Ltd. and Shanghai Yan'an Vientiane Pharmaceutical Co., Ltd. have been invested and controlled by Shanghai Sheng Pharmaceutical Sales Co., Ltd. of the material technology industrial park. It has formed a pharmaceutical industry integrating R & D, production and sales. The pharmaceutical industry is becoming one of the important profit growth points of the company. In terms of financial investment, the company invested 230 million yuan in Changjiang Securities Company with its own funds, accounting for 10% of its registered capital of 2 billion yuan after capital increase. Changxin Fund Management Co., Ltd., jointly sponsored by the company, Changjiang Securities and WISCO, was established in May 2003 with a registered capital of 90 million yuan, of which 34.33% was invested by the company. The future business objectives of the enterprise are: to maintain the sustained and steady growth of business performance, to further expand the scale and market share of the main textile industry, to accelerate the adjustment of the company's industrial structure; to increase the proportion of clothing fabrics with considerable profit space, to rapidly develop and expand the plush clothing industry, to make it a new important profit growth point; to increase the development of new products in the textile industry, and to improve The proportion of high-tech products in sales volume, actively expand the domestic and foreign textile market; integrate the rudimentary pharmaceutical industry and make considerable profits; strengthen enterprise management and corporate culture construction according to the actual and development requirements of cross industry and transnational operation of the company. Explore the management mode of international enterprise groups across industries and regions, and maintain a steady growth in the main business income and net profit. In the next five years, we will strive to increase the construction and scale of enterprises from 1.8 billion yuan in net assets to 3 billion yuan; increase the total annual net profit from 157 million yuan to 350 million yuan, and form a diversified industrial development pattern integrating fine textile, biomedicine and financial investment.
浙公网安备 33011802001999号
